Aktienanalyse zu Savara Inc (SVRA)SVRASavara Inc

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Savara Inc is currently not a good buy due to its low current price of $4.22 and an RSI of 23.349, indicating oversold conditions. While there is potential upside with a price target of $12 from JPMorgan, the company is facing significant losses, with a projected net income loss of $37,284,000 in Q1 2026. The upcoming FDA decision on Molbreevi on November 22 could be a turning point, but the current financial performance and negative trends suggest caution.

5 analysts cover SVRA: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 10.17.